vs
爱齐科技（ALGN）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
爱齐科技的季度营收约是登士柏西诺德的1.1倍（$1.0B vs $961.0M）。爱齐科技净利率更高（13.0% vs -15.2%，领先28.2%）。登士柏西诺德同比增速更快（6.2% vs 5.3%）。爱齐科技自由现金流更多（$187.3M vs $60.0M）。过去两年爱齐科技的营收复合增速更高（2.5% vs 0.4%）
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
ALGN vs XRAY — 直观对比
营收规模更大
ALGN
是对方的1.1倍
$961.0M
营收增速更快
XRAY
高出0.9%
5.3%
净利率更高
ALGN
高出28.2%
-15.2%
自由现金流更多
ALGN
多$127.3M
$60.0M
两年增速更快
ALGN
近两年复合增速
0.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $961.0M |
| 净利润 | $135.8M | $-146.0M |
| 毛利率 | 65.3% | 46.1% |
| 营业利润率 | 14.8% | -14.5% |
| 净利率 | 13.0% | -15.2% |
| 营收同比 | 5.3% | 6.2% |
| 净利润同比 | 30.8% | 66.0% |
| 每股收益（稀释后） | $1.88 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGNXRAY
| Q4 25 | $1.0B | $961.0M | ||
| Q3 25 | $995.7M | $904.0M | ||
| Q2 25 | $1.0B | $936.0M | ||
| Q1 25 | $979.3M | $879.0M | ||
| Q4 24 | $995.2M | $905.0M | ||
| Q3 24 | $977.9M | $951.0M | ||
| Q2 24 | $1.0B | $984.0M | ||
| Q1 24 | $997.4M | $953.0M |
净利润ALGNXRAY
| Q4 25 | $135.8M | $-146.0M | ||
| Q3 25 | $56.8M | $-427.0M | ||
| Q2 25 | $124.6M | $-45.0M | ||
| Q1 25 | $93.2M | $20.0M | ||
| Q4 24 | $103.8M | $-430.0M | ||
| Q3 24 | $116.0M | $-494.0M | ||
| Q2 24 | $96.6M | $-4.0M | ||
| Q1 24 | $105.0M | $18.0M |
毛利率ALGNXRAY
| Q4 25 | 65.3% | 46.1% | ||
| Q3 25 | 64.2% | 48.8% | ||
| Q2 25 | 69.9% | 52.4% | ||
| Q1 25 | 69.5% | 53.0% | ||
| Q4 24 | 70.0% | 49.3% | ||
| Q3 24 | 69.7% | 52.1% | ||
| Q2 24 | 70.3% | 51.9% | ||
| Q1 24 | 70.0% | 53.1% |
营业利润率ALGNXRAY
| Q4 25 | 14.8% | -14.5% | ||
| Q3 25 | 9.7% | -24.1% | ||
| Q2 25 | 16.1% | -13.7% | ||
| Q1 25 | 13.4% | 7.2% | ||
| Q4 24 | 14.5% | -56.2% | ||
| Q3 24 | 16.6% | -48.6% | ||
| Q2 24 | 14.3% | 5.1% | ||
| Q1 24 | 15.5% | 4.4% |
净利率ALGNXRAY
| Q4 25 | 13.0% | -15.2% | ||
| Q3 25 | 5.7% | -47.2% | ||
| Q2 25 | 12.3% | -4.8% | ||
| Q1 25 | 9.5% | 2.3% | ||
| Q4 24 | 10.4% | -47.5% | ||
| Q3 24 | 11.9% | -51.9% | ||
| Q2 24 | 9.4% | -0.4% | ||
| Q1 24 | 10.5% | 1.9% |
每股收益（稀释后）ALGNXRAY
| Q4 25 | $1.88 | $-0.74 | ||
| Q3 25 | $0.78 | $-2.14 | ||
| Q2 25 | $1.72 | $-0.22 | ||
| Q1 25 | $1.27 | $0.10 | ||
| Q4 24 | $1.40 | $-2.09 | ||
| Q3 24 | $1.55 | $-2.46 | ||
| Q2 24 | $1.28 | $-0.02 | ||
| Q1 24 | $1.39 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $326.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $4.0B | $1.3B |
| 总资产 | $6.2B | $5.4B |
| 负债/权益比越低杠杆越低 | — | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资ALGNXRAY
| Q4 25 | $1.1B | $326.0M | ||
| Q3 25 | $1.0B | $363.0M | ||
| Q2 25 | $901.2M | $359.0M | ||
| Q1 25 | $873.0M | $398.0M | ||
| Q4 24 | $1.0B | $272.0M | ||
| Q3 24 | $1.0B | $296.0M | ||
| Q2 24 | $761.4M | $279.0M | ||
| Q1 24 | $865.8M | $291.0M |
总债务ALGNXRAY
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALGNXRAY
| Q4 25 | $4.0B | $1.3B | ||
| Q3 25 | $4.0B | $1.5B | ||
| Q2 25 | $3.9B | $2.0B | ||
| Q1 25 | $3.8B | $2.0B | ||
| Q4 24 | $3.9B | $1.9B | ||
| Q3 24 | $3.9B | $2.5B | ||
| Q2 24 | $3.8B | $3.1B | ||
| Q1 24 | $3.8B | $3.3B |
总资产ALGNXRAY
| Q4 25 | $6.2B | $5.4B | ||
| Q3 25 | $6.2B | $5.7B | ||
| Q2 25 | $6.2B | $6.1B | ||
| Q1 25 | $6.1B | $6.0B | ||
| Q4 24 | $6.2B | $5.8B | ||
| Q3 24 | $6.4B | $6.6B | ||
| Q2 24 | $6.2B | $6.9B | ||
| Q1 24 | $6.2B | $7.1B |
负债/权益比ALGNXRAY
| Q4 25 | — | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $223.2M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $187.3M | $60.0M |
| 自由现金流率自由现金流/营收 | 17.9% | 6.2% |
| 资本支出强度资本支出/营收 | 3.4% | 4.3% |
| 现金转化率经营现金流/净利润 | 1.64× | — |
| 过去12个月自由现金流最近4个季度 | $490.8M | $104.0M |
8季度趋势，按日历期对齐
经营现金流ALGNXRAY
| Q4 25 | $223.2M | $101.0M | ||
| Q3 25 | $188.7M | $79.0M | ||
| Q2 25 | $128.7M | $48.0M | ||
| Q1 25 | $52.7M | $7.0M | ||
| Q4 24 | $286.1M | $87.0M | ||
| Q3 24 | $263.7M | $141.0M | ||
| Q2 24 | $159.8M | $208.0M | ||
| Q1 24 | $28.7M | $25.0M |
自由现金流ALGNXRAY
| Q4 25 | $187.3M | $60.0M | ||
| Q3 25 | $169.0M | $40.0M | ||
| Q2 25 | $107.2M | $16.0M | ||
| Q1 25 | $27.4M | $-12.0M | ||
| Q4 24 | $263.1M | $36.0M | ||
| Q3 24 | $233.9M | $98.0M | ||
| Q2 24 | $106.4M | $156.0M | ||
| Q1 24 | $19.3M | $-9.0M |
自由现金流率ALGNXRAY
| Q4 25 | 17.9% | 6.2% | ||
| Q3 25 | 17.0% | 4.4% | ||
| Q2 25 | 10.6% | 1.7% | ||
| Q1 25 | 2.8% | -1.4% | ||
| Q4 24 | 26.4% | 4.0% | ||
| Q3 24 | 23.9% | 10.3% | ||
| Q2 24 | 10.3% | 15.9% | ||
| Q1 24 | 1.9% | -0.9% |
资本支出强度ALGNXRAY
| Q4 25 | 3.4% | 4.3% | ||
| Q3 25 | 2.0% | 4.3% | ||
| Q2 25 | 2.1% | 3.4% | ||
| Q1 25 | 2.6% | 2.2% | ||
| Q4 24 | 2.3% | 5.6% | ||
| Q3 24 | 3.0% | 4.5% | ||
| Q2 24 | 5.2% | 5.3% | ||
| Q1 24 | 0.9% | 3.6% |
现金转化率ALGNXRAY
| Q4 25 | 1.64× | — | ||
| Q3 25 | 3.33× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 0.57× | 0.35× | ||
| Q4 24 | 2.76× | — | ||
| Q3 24 | 2.27× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 0.27× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGN
暂无分部数据
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
